© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 18, 1557-1563,
September 15, 1999
© 1999 Oxford University Press
REPORTS |
Combination Photoimmunotherapy and Cisplatin: Effects on Human Ovarian Cancer Ex Vivo
Affiliations of authors: L. R. Duska, Wellman Laboratories of Photomedicine and Vincent Memorial Obstetrics and Gynecology Service, Harvard Medical School, Massachusetts General Hospital, Boston; M. R. Hamblin, J. L. Miller, T. Hasan, Department of Dermatology, Wellman Laboratories of Photomedicine, Harvard Medical School, Massachusetts General Hospital.
Correspondence to: Tayyaba Hasan, Ph.D., Department of Dermatology, Wellman Laboratories of Photomedicine, Harvard Medical School, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 (e-mail: hasan{at}helix.harvard.mgh.edu).
BACKGROUND: Patients with ovarian cancer that is clinically resistant to cisplatin-based chemotherapy have little hope of a cure of their disease. Photoimmunotherapy, which involves the antibody-targeted delivery of a nontoxic photosensitizer that is activated to a cytotoxic state with visible light, may offer a new treatment option. Photoimmunotherapy may be applied intraperitoneally to target disseminated tumor. We tested the hypothesis that this treatment in combination with cisplatin potentiates cytotoxicity in ovarian cancer cell lines and primary cultures of human tumors. METHODS: Five human cancer cell lines (ovarian and breast) and 19 primary cultures were studied. The primary cultures were from solid and ascites tumor samples obtained from 14 patients with ovarian cancer who were undergoing primary surgery. The photosensitizer chlorin e6 was conjugated to the F(ab')2 fragment of the murine monoclonal antibody OC-125, which is directed against the antigen CA 125. Cytotoxicity was measured by the microculture tetrazolium assay. Treatments consisted of cisplatin alone, photoimmunotherapy alone, and photoimmunotherapy followed by cisplatin. The fractional product method was used to assess synergy in treatment effects. Ex vivo cultured human cells exhibiting 80% or greater survival at cisplatin concentrations of 10 µM for 24 hours were defined as cisplatin resistant for this study. RESULTS: When all cell types (cisplatin sensitive and cisplatin resistant) were considered together, combination treatment yielded cytotoxicity that was, on average, 6.9 times (95% confidence interval = 1.86-11.94) greater than that of cisplatin alone (two-sided P = .023). Cisplatin-resistant cells showed a synergistic effect of the two treatments (two-sided P = .044), while cisplatin-sensitive cells showed an additive effect. CONCLUSION: These ex vivo data suggest that platinum resistance in human ovarian cancer cells may be reversible by pretreatment with OC-125-targeted photoimmunotherapy. Further studies are required to confirm the efficacy of this approach in vivo.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Anand, G. Honari, T. Hasan, P. Elson, and E. V. Maytin Low-Dose Methotrexate Enhances Aminolevulinate-Based Photodynamic Therapy in Skin Carcinoma Cells In vitro and In vivo Clin. Cancer Res., May 15, 2009; 15(10): 3333 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. del Carmen, I. Rizvi, Y. Chang, A. C. E. Moor, E. Oliva, M. Sherwood, B. Pogue, and T. Hasan Synergism of Epidermal Growth Factor Receptor-Targeted Immunotherapy With Photodynamic Treatment of Ovarian Cancer In Vivo J Natl Cancer Inst, October 19, 2005; 97(20): 1516 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Marco Del Governatore, M. R. Hamblin, C. R. Shea, I. Rizvi, K. G. Molpus, K. K. Tanabe, and T. Hasan Experimental Photoimmunotherapy of Hepatic Metastases of Colorectal Cancer with a 17.1A Chlorine6 Immunoconjugate Cancer Res., August 1, 2000; 60(15): 4200 - 4205. [Abstract] [Full Text]
|
|
|
|
|
|
H. Miayake, A. Tolcher, and M. E. Gleave Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides J Natl Cancer Inst, January 5, 2000; 92(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Iinuma, K. T. Schomacker, G. Wagnieres, M. Rajadhyaksha, M. Bamberg, T. Momma, and T. Hasan In Vivo Fluence Rate and Fractionation Effects on Tumor Response and Photobleaching: Photodynamic Therapy with Two Photosensitizers in an Orthotopic Rat Tumor Model Cancer Res., December 1, 1999; 59(24): 6164 - 6170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Tochner, S. Hahn, and E. Glatstein Photoimmunotherapy and Ovarian Cancer: an Improbable Fiction or a Palpable Hit? J Natl Cancer Inst, September 15, 1999; 91(18): 1526 - 1527. [Full Text] [PDF]
|
|